CDK-TCIP2

CAT: 0804-HY-169245-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-169245-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
DK-TCIP2, linking inhibitor of CDK9 SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer[1].
UNSPSC
12352005
Target
BCL6; CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk-tcip2.html
Purity
98.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(OCC(NC)=O)=CC2=C(N1C)C(OC)=CC(NC3=NC(N4CCC(CC4)C(N5CCC6(CCN(C(CN7CCC(CC7)C(NC8=NC=C(SCC9=NC=C(C(C)(C)C)O9)S8)=O)=O)CC6)CC5)=O)=NC=C3Cl)=C2
Molecular Formula
C52H67ClN12O8S2
Molecular Weight
1087.75
References & Citations
[1]Sarott RC, et al. Relocalizing transcriptional kinases to activate apoptosis. Science. 2024 Oct 4;386 (6717) :eadl5361.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-169244-01CDK-TCIP1
HY-150641-01CDK-IN-9
HY-168067CDK-IN-14
HY-147386-01CDK-IN-10
HY-170507CDK-IN-16
HY-149173-01CDK-IN-11
HY-13033-01CDK-IN-2
HY-201330CDK-IN-18
HY-78428-01CDK-IN-6
HY-168134CDK-IN-15

Alternative Products

CatalogName
MF-0110608-01CDK-TCIP2
MBS5804923CDK-IN-9
BUP12701-01CDK-IN-2
MF-0112750-01CDK-IN-16
M35483-01CDK-IN-10
MBS5797812-01CDK-IN-6
MBS5817050CDK-IN-12
MF-0110600-01CDK-IN-15
MF-0120141-01CDK-IN-11
MF-0116274-01CDK-IN-13

Popular Products